Stock Financial Ratios, Dividends, Split History

WSTC / West Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,966.02
Book Value ($M)-324.50
Book Value / Share-3.88
Price / Book-6.06
NCAV ($M)-3,072.52
NCAV / Share-36.73
Price / NCAV-0.64
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 82,969,000
Weighted Average Number Of Diluted Shares Outstanding 84,599,000
Common Shares Outstanding 83,352,467
Common Stock Shares Outstanding 83,265
Shares Outstanding 83,264,912
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.07
Return on Assets (ROA)0.05
Return on Equity (ROE)-0.35
Balance Sheet (mrq) ($M)
Quick Ratio1.40
Current Ratio1.51
Income Statement (mra) ($M)
Operating Income444.21
Net Income193.39
Earnings Per Share Basic2.33
Earnings Per Share Diluted2.29
Cash Flow Statement (mra) ($M)
Cash From Operations428.27
Cash from Investing-108.26
Cash from Financing-108.26
Identifiers and Descriptors
Central Index Key (CIK)1024657
Related CUSIPS
952355904 952355105 952355954

Split History

Stock splits are used by West Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

The Latest Housing Market Index And Builder Confidence - A Signal For Real Estate?

10h seekingalpha
The Housing Market Index was reported for the month of July this week. While the data was unchanged, it was still lower than highs reached late last year.

Germans scared, Chinese relaxed: Trump-Putin meeting reverberates around world | Euronews

2018-07-17 euronews
LONDON — The press conference between presidents Donald Trump and Vladimir Putin prompted widespread shock and derision across the United States.

Red River awards PYBAR contract extension for West 45 mine

Red River Resources has awarded PYBAR Mining Services an extension to its contract for the West 45 underground zinc-lead mine.

Call Centers in the U.S. Pacific Compete with Mainland U.S. Providers Under Minimum Wage Requirements

2018-07-09 accesswire
AGANA, GUAM / ACCESSWIRE / July 9, 2018 / The U.S. Pacific Islands and the Associated Territories of the U.S. are emerging into the communications outsourcing industry offering very competitive hourly rates that are attractive to high call volume clients running campaigns in the private and non-profit sector, or for political awareness and fundraising purposes.

UPDATE 1-NY jury convicts two men for trading on hacked press releases

2018-07-07 reuters
NEW YORK (Reuters) - A federal jury in Brooklyn, New York on Friday convicted two men for their roles in an international scheme to make millions of dollars by illegally trading on corporate press releases that were stolen by computer hackers before they became public. (34-0)

CUSIP: 952355204